Headlines Covid-19 Specialties Trending Feeds Videos

John V. Heymach, MD, PhD, discusses the potential utility of afatinib in NRG1 fusion–positive non–small cell lung...

The FDA has approved nivolumab to be combined with select types of chemotherapy for the frontline treatment of patients with advanced or metastatic gastric...

Nivolumab plus ipilimumab was found to induce significant antitumor activity when administered to patients with metastatic castration-resistant prostate cancer and immunogenic...

Sumanta K. Pal, MD, details ongoing research efforts dedicated to providing additional therapeutic options for patients with renal cell carcinoma in the second-line setting...

Nivolumab in combination with paclitaxel showed clinical activity and a manageable safety profile when used as second-line therapy for patients with Epstein-Barr virus–related, microsatellite...

  • Nivolumab in combination with paclitaxel showed clinical activity and a manageable safety profile when used as second-line therapy for patients with Epstein-Barr virus–related, MSI–H/MMRD or PD-L1+ advanced gastric cancer. @AACR #AACR21 #gicsm https://t.co/BuTJcdwK7I - view on twitter

Nicolaus Kröger, MD, discusses the role of allogenic stem cell transplant in patients with multiple...

The addition of ipilimumab to nivolumab as an adjuvant treatment failed to improve relapse-free survival in the intent-to-treat and PD-L1 of less than 1%...

Missak Haigentz Jr., MD, discusses the importance of adjuvant osimertinib in EGFR-positive non–small cell lung...

Mashup Score:2

OncLive

Risk Factors Associated With TA-TMA - 2 days

Mashup Score:2

Jeffrey Laurence, MD, reviews the risk factors for developing transplant-associated thrombotic microangiopathy, and the panel discusses how risk affects their decision to change or...

The tumor-infiltrating lymphocyte therapy lifileucel was found to elicit durable responses in patients with advanced melanoma who were previously treated with an immune checkpoint...